Diabetes is a complex metabolic disease that affects more than 340 million individuals worldwide. Around 20% of these patients develop diabetic wounds. Diabetic foot ulcers (DFUs) are a common complication of diabetes that are recalcitrant to healing due to persistent inflammation. Only one FDA-approved medicine, becaplermin, is used to treat DFUs, but it is not the first-line therapy because of its low efficacy and higher risk of cancer and mortality. The absence of effective and safe treatment has necessitated the development of more effective medications or procedures. The mechanism underlying this process, however, remains unknown, prompting further research into diabetic foot ulcer etiology.
The development of diabetic wounds is a serious complication for patients with diabetes. Peripheral neuropathy, foot deformity, external trauma, peripheral vascular disease, and peripheral oedema are just a few of the contributing elements that lead to foot ulcers in diabetic individuals. Infection is widespread in DFUs, resulting in the patient’s protracted hospitalization and psychological issues. A better understanding of pathogenic variables can aid in the development of innovative treatments for poor healing.
The aim of this Research Topic is to provide a forum focusing on the pathogenesis of DFUs. An understanding of the critical pathways involved will guide future therapies against DFUs. Studies investigating contributing factors of diabetic foot in vitro and in vivo, as well as human clinical samples, are encouraged to accelerate the development of innovative therapies and drugs. Manuscripts relating to DFUs focusing on, but are not limited to, the following topics are invited in this Research Topic:
• Identification of new biological pathways and mechanisms
• Clinical data sets
• Therapeutic regimens for the management of DFUs
Diabetes is a complex metabolic disease that affects more than 340 million individuals worldwide. Around 20% of these patients develop diabetic wounds. Diabetic foot ulcers (DFUs) are a common complication of diabetes that are recalcitrant to healing due to persistent inflammation. Only one FDA-approved medicine, becaplermin, is used to treat DFUs, but it is not the first-line therapy because of its low efficacy and higher risk of cancer and mortality. The absence of effective and safe treatment has necessitated the development of more effective medications or procedures. The mechanism underlying this process, however, remains unknown, prompting further research into diabetic foot ulcer etiology.
The development of diabetic wounds is a serious complication for patients with diabetes. Peripheral neuropathy, foot deformity, external trauma, peripheral vascular disease, and peripheral oedema are just a few of the contributing elements that lead to foot ulcers in diabetic individuals. Infection is widespread in DFUs, resulting in the patient’s protracted hospitalization and psychological issues. A better understanding of pathogenic variables can aid in the development of innovative treatments for poor healing.
The aim of this Research Topic is to provide a forum focusing on the pathogenesis of DFUs. An understanding of the critical pathways involved will guide future therapies against DFUs. Studies investigating contributing factors of diabetic foot in vitro and in vivo, as well as human clinical samples, are encouraged to accelerate the development of innovative therapies and drugs. Manuscripts relating to DFUs focusing on, but are not limited to, the following topics are invited in this Research Topic:
• Identification of new biological pathways and mechanisms
• Clinical data sets
• Therapeutic regimens for the management of DFUs
